A5073572288- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- PI3K/AKT/mTOR signaling in cancer
- Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Genetic factors in colorectal cancer
- Economic and Financial Impacts of Cancer
- Occupational and environmental lung diseases
- Breast Cancer Treatment Studies
- Cancer therapeutics and mechanisms
- Chronic Lymphocytic Leukemia Research
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Chemotherapy-induced cardiotoxicity and mitigation
- Radiopharmaceutical Chemistry and Applications
- Advanced Breast Cancer Therapies
- Medical Imaging and Pathology Studies
- Cancer Research and Treatments
The Maria Sklodowska-Curie National Research Institute of Oncology
2016-2025
Foundation for Polish Science
2024
National Institute of Oncology
2021-2023
Centrum Onkologii
2012-2021
Pierre Fabre (France)
2004-2021
Centrum Medyczne Kształcenia Podyplomowego
2017
Zachodniopomorskie Centrum Onkologii
2016
Centralny Szpital Kliniczny
2016
Wojskowy Instytut Medyczny
2016
Polskie Towarzystwo Gastroenterologii
2015
PURPOSE: To compare the efficacy and tolerability of anastrozole (Arimidex; AstraZeneca, Wilmington, DE, Macclesfield, United Kingdom) with that tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal women. PATIENTS AND METHODS: This randomized, double-blind, multicenter study evaluated 1 mg once daily relative to 20 patients tumors were hormone receptor–positive or unknown receptor status who eligible endocrine therapy. The primary end points time progression...
To assess the efficacy and safety of zoledronic acid in patients with bone metastases secondary to solid tumors other than breast or prostate cancer.Patients were randomly assigned receive (4 8 mg) placebo every 3 weeks for 9 months, concomitant antineoplastic therapy. The 8-mg dose was reduced 4 mg (8/4-mg group). primary analysis proportion at least one skeletal-related event (SRE), defined as pathologic fracture, spinal cord compression, radiation therapy bone, surgery bone. Secondary...
The authors previously reported the efficacy of a dose 4 mg zoledronic acid in reducing skeletal complications patients with bone metastases secondary to lung carcinoma and other solid tumors (except carcinomas breast prostate). In current study, they update these results report long-term safety 21 months treatment randomized, placebo-controlled trial.A total 773 were randomized receive (4 or 8 mg) placebo via 15-minute infusion every 3 weeks for months. 8-mg later was reduced (8/4-mg...
Increased hepatocyte growth factor/MET signaling is associated with poor prognosis and acquired resistance to epidermal factor receptor (EGFR) -targeted drugs in patients non-small-cell lung cancer (NSCLC). We investigated whether dual inhibition of MET/EGFR results clinical benefit NSCLC.Patients recurrent NSCLC were randomly assigned at a ratio one receive onartuzumab plus erlotinib or placebo erlotinib; crossover was allowed progression. Tumor tissue required assess MET status by...
PURPOSE This phase III, multicenter, randomized, placebo-controlled trial assessed the efficacy and safety of sorafenib, an oral multikinase inhibitor, in combination with carboplatin paclitaxel chemotherapy-naïve patients unresectable stage IIIB or IV non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Nine hundred twenty-six were randomly assigned to receive up six 21-day cycles area under curve 6 200 mg/m(2) (CP) on day 1, followed by either sorafenib 400 mg twice a (n = 464, arm A)...
This randomized, multicenter, phase III study compared doxorubicin and docetaxel (AT) with cyclophosphamide (AC) as first-line chemotherapy (CT) in metastatic breast cancer (MBC).Patients (n = 429) were randomly assigned to receive 50 mg/m(2) plus 75 214) or 60 600 215) on day 1, every 3 weeks for up eight cycles.Time progression (TTP; primary end point) time treatment failure (TTF) significantly longer AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 23.7...
This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients advanced non-small-cell lung cancer (NSCLC).
Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC). This trial was undertaken to determine whether adjuvant treatment the metalloproteinase inhibitor marimastat could prolong survival responding patients SCLC after chemotherapy.SCLC complete or partial remission were eligible. They stratified by radiotherapy (early, late, none), stage (extensive limited), response (complete partial), and cooperative group (National Cancer Institute...
Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non-small-cell lung cancer (NSCLC), based on the importance of signaling pathways involved tumor growth, angiogenesis, and metastasis. This phase III trial investigated overall survival (OS) for sunitinib versus placebo patients refractory NSCLC.Patients previously treated one to two chemotherapy regimens (including platinum-based regimen) recurrent NSCLC, whom was indicated, were randomly assigned...
7505 Background: Met is associated with a poor outcome in many cancers, including NSCLC. activation mechanism of resistance to EGFR inhibition, supporting dual inhibition Met/EGFR. MetMAb monovalent monoclonal antibody that specifically binds the receptor. Methods: OAM4558g global randomized, double-blind phase II study comparing plus erlotinib (ME) placebo (PE) 2nd/3rd line Tissue collection was mandatory assess c-Met IHC expression levels (Met Dx). Co-primary endpoints were PFS Dx+ and ITT...
3 Background: Epidermal growth factor receptor (EGFR) dysregulation is common in NSCLC and associated with poorer prognosis. This phase III study assessed the efficacy safety of EGFR-targeted monoclonal antibody cetuximab combination cisplatin/vinorelbine (CV) compared CV alone advanced NSCLC. Methods: Patients EGFR- detectable were randomized 1:1 to (400 mg/m2 initial dose, then 250 mg/m2/wk) plus C (80 d1) V (25 d1, d8) q3w (arm A) or B). The primary endpoint was overall survival (OS);...
Figitumumab (CP-751,871), a fully human immunoglobulin G2 monoclonal antibody, inhibits the insulin-like growth factor 1 receptor (IGF-1R). Our multicenter, randomized, phase III study compared figitumumab plus chemotherapy with alone as first-line treatment in patients advanced non-small-cell lung cancer (NSCLC).